Novartis India Faces ₹5056 Crore Open Offer as WaveRise, ChrysCapital Submit Statement

The total value of the open offer is ₹5,056.74 crore, and FY2024 revenue stood at ₹257.33 crore.
Reader Takeaway: Large open offer signals potential delisting; subdued profitability remains a pressure point.

What just happened (today’s filing)

Novartis India Limited has officially acknowledged receipt of the Detailed Public Statement (DPS) concerning an open offer.

The statement, dated February 26, 2026, originates from WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners, along with their associated parties. This formal acceptance signifies compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations.

The public announcement of the open offer was initially made on February 19, 2026. The acquisition plan is set to open on February 27, 2026, and will conclude on March 12, 2026.

Why this matters

This development is crucial as it indicates a significant move by the investment consortium to acquire a substantial stake in Novartis India.

Such offers often precede a potential delisting of the company from the stock exchanges, which could lead to a change in its ownership structure and strategic direction. For existing shareholders, it represents an opportunity for liquidity at a specified price.

The backstory (grounded)

Novartis India Limited, a subsidiary of the global pharmaceutical giant Novartis AG, has been a player in the Indian market, marketing and distributing various pharmaceutical products. [cite:GROUNDED_RESEARCH_1]

WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners are investment entities. ChrysCapital is a well-established private equity firm known for its investments in Indian companies. [cite:GROUNDED_RESEARCH_2]

Reports suggest that this open offer is a strategic move by these investors to consolidate ownership, potentially with the aim of delisting the company. [cite:GROUNDED_RESEARCH_3]

What changes now

• Existing public shareholders will have the option to tender their shares during the open offer period.
• The offer price represents a significant premium or valuation benchmark for the company's equity.
• If successful, the acquirers will gain control of a larger, potentially consolidated, entity.
• A successful delisting would mean Novartis India would cease to be a publicly traded company on Indian exchanges.

Risks to watch

Shareholders should monitor the regulatory approvals required for the open offer to proceed smoothly.

Execution risk in completing the offer within the stipulated timeline and at the offered price is also a factor.

While no significant negative history was found, the pharmaceutical sector always carries inherent regulatory compliance and market access risks. [cite:GROUNDED_RESEARCH_6]

Peer comparison

Novartis India operates in a competitive landscape alongside major pharmaceutical players like Sun Pharmaceutical Industries Ltd., Cipla Ltd., and Dr. Reddy's Laboratories Ltd. [cite:GROUNDED_RESEARCH_4, 5]

These peers are significantly larger in terms of revenue and profitability, highlighting the scale difference. For instance, Sun Pharma reported FY2024 revenues of approximately ₹43,000 crore, with a net profit of around ₹4,000 crore. [cite:GROUNDED_RESEARCH_7]

Context metrics (time-bound)

• For the year ended December 31, 2024, Novartis India reported total revenue of ₹257.33 crore and a net profit of ₹2.09 crore, with a net worth of ₹409.64 crore.
• In the previous year, ended December 31, 2023, revenue was ₹228.82 crore, net profit ₹1.56 crore, and net worth ₹396.03 crore.

What to track next

• Monitor official announcements regarding any regulatory clearances for the open offer.
• Track shareholder response and the number of shares tendered during the open offer period.
• Observe any further strategic announcements from Novartis India or the acquiring consortium post-offer.